Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance
Author:
Affiliation:
1. US Real-World Value and Evidence, Janssen Scientific Affairs, LLC, Titusville, NJ, USA
2. Analysis Group, Inc, Montréal, QC, Canada
Publisher
Informa UK Limited
Subject
General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/03007995.2023.2239045
Reference30 articles.
1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health (HHS Publication No. PEP21-07-01-003, NSDUH series H-56). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021.
2. Major depressive disorder
3. Mayo Clinic. Depression (major depressive disorder); [cited 2020 Mar 18]. Available from: https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
4. World Health Organization. Depression; [cited 2020 Mar 18]. Available from: https://www.who.int/news-room/fact-sheets/detail/depression
5. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray;Current Medical Research and Opinion;2024-07-24
2. Efficacy of Esketamine among patients with treatment resistant depression in a ‘real world' health-care setting in Israel;Journal of Psychiatric Research;2024-06
3. Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States;Drugs - Real World Outcomes;2024-05-10
4. Treatment Attrition, Concomitant Pharmaceutical Use, Temporal Claims-Based Utilization, and Real-World Characteristics Among Esketamine New Initiators in the United States, 2019-2022;2024-04-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3